更新于：2024-11-18
Famotidine
法莫替丁
更新于：2024-11-18
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
137
项与 法莫替丁 相关的临床试验A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
Bioequivalence study of Famotidine 40 mg tablet manufactured by Sanamed company versus the originator brand in healthy volunteers
A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Famotidine 40mg tablet of Amin Pharm Co., IRAN in comparison of Famodin® 40mg tablet of Sandoz in 24 healthy adult subjects under fasting condition
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
2,302
项与 法莫替丁 相关的文献（医药）2025-01-01BEHAVIOURAL BRAIN RESEARCH
Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model
Article
作者: Godad, Angel ; Sequeira, Ronnita C
Alzheimer's disease (AD), a chronic neurodegenerative disease, presents a substantial global health challenge. This study explored the potential therapeutic role of famotidine, a histamine (H2) receptor antagonist, as a glycogen synthase kinase-3β (GSK-3β) inhibitor in the context of AD induced by aluminium chloride (AlCl3) in a rat model. The intricate relationship between GSK-3β dysregulation and AD pathogenesis, particularly in amyloid-β (Aβ) production, formed the basis for investigating famotidine's efficacy. Molecular modelling revealed famotidine's efficient binding to GSK-3β, suggesting inhibitory potential. In behavioural assessments, famotidine-treated groups exhibited dose-dependent improvements in Morris Water Maze, Novel Object Recognition, and Y-Maze tests, comparable to the standard Rivastigmine tartrate group. Biochemical analyses showed that famotidine inhibits acetylcholinesterase, decreases lipid peroxidation, increases antioxidant activity, and mitigates oxidative stress. Moreover, famotidine significantly lowered the levels of GSK-3β, IL-6, and Aβ(1-42). The neuroprotective effects of famotidine were further supported by histopathological analysis. This comprehensive investigation underscores famotidine's potential as a GSK-3β inhibitor, providing insights into its therapeutic impact on AD induced by AlCl3. The study offers a promising avenue for repurposing famotidine due to its established safety profile and widespread availability, highlighting its potential in addressing the formidable challenge of AD.
2024-11-01BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Structural basis for the binding of famotidine, cimetidine, guanidine, and pimagedine with serine protease
Article
作者: Ahmad, Malik Shoaib ; Akbar, Zeeshan ; Kalam, Noor ; Choudhary, M. Iqbal ; Rasheed, Saima ; Shah, Nayab ; Choudhary, M Iqbal
Serine proteases are among the important groups of enzymes having significant roles in cell biology. Trypsin is a representative member of the serine superfamily of enzymes, produced by acinar cells of pancreas. It is a validated drug target for various ailments including pancreatitis and colorectal cancer. Premature activation of trypsin is involved in the lysis of pancreatic tissues, which causes pancreatitis. It is also reported to be involved in colorectal carcinoma by activating other proteases, such as matrix metalloproteinase (MMPs). The development of novel trypsin inhibitors with good pharmacokinetic properties could play important roles in pharmaceutical sciences. This study reports the crystal structures of bovine pancreatic trypsin with four molecules; cimetidine, famotidine, pimagedine, and guanidine. These compounds possess binding affinity towards the active site (S1) of trypsin. The structures of all four complexes provided insight of the binding of four different ligands, as well as the dynamics of the active site towards the bind with different size ligands. This study might be helpful in designing of new potent inhibitors of trypsin and trypsin like serine proteases.
2024-11-01Small
Residue‐Free Orally Administered Drug Carrier Based on a Porous Aromatic Framework for Efficient Multisite Treatment
Article
作者: Sun, Hanjun ; Liu, Kangning ; Zhao, Yun ; Xi, Enpeng ; Gao, Nan ; Zhu, Guangshan ; Yuan, Ye ; Ding, Qi ; Yang, Fuming
Abstract:
Nowadays, oral medications are the primary method of treating disease due to their convenience, low cost, and safety, without the need for complex medical procedures. To maximize treatment effectiveness, almost all oral medications utilize drug carriers, such as capsules, liposomes, and sugar coatings. However, these carriers rely on dissolution or fragmentation to achieve drug release, which leads to drugs and carriers coabsorption in the body, causing unnecessary adverse drug reactions, such as nausea, vomiting, abdominal pain, and even death caused by allergy. Therefore, the ideal oral drug carrier should avoid degradation and absorption and be totally excreted after drug release at the desired location. Herein, a gastrointestinally stable oral drug carrier based on porous aromatic framework‐1 (PAF‐1) is constructed, and it is modified with famotidine (a well‐known gastric drug) and mesalazine (a well‐known ulcerative colitis drug) to verify the excellent potential of PAF‐1. The results demonstrate that PAF‐1 can accurately release famotidine in stomach, mesalazine in the intestine, and finally be completely excreted from the body without any residue after 12 h. The use of PAF materials for the construction of oral drug carriers with no residue in the gastrointestinal tract provides a new approach for efficient disease treatment.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 | |
| Zollinger-Ellison综合征 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV感染 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 80 | (Famotidine) | 壓糧壓糧齋憲簾糧壓淵(觸衊壓齋餘鹹餘憲蓋齋) = 積鹹蓋夢鏇鑰獵顧積衊 觸壓簾獵壓廠願簾簾願 (蓋壓糧窪構網鑰蓋範淵, 鏇遞獵膚淵觸觸窪構範 ~ 齋餘製願鏇繭觸衊鹹襯) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 壓糧壓糧齋憲簾糧壓淵(觸衊壓齋餘鹹餘憲蓋齋) = 淵鬱遞鹹築鹽廠醖遞鑰 觸壓簾獵壓廠願簾簾願 (蓋壓糧窪構網鑰蓋範淵, 憲憲壓鏇夢製築壓選築 ~ 遞衊淵鹽壓糧繭壓餘選) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 簾憲蓋壓蓋範遞蓋衊網(積衊蓋築網鏇簾餘膚艱) = 鬱繭餘願艱範網糧鏇築 廠壓糧襯壓艱艱遞窪艱 (網積繭蓋淵餘鑰顧觸憲, 鹹壓襯艱憲構艱顧餘範 ~ 簾鹽窪膚築鏇衊遞糧選) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 簾憲蓋壓蓋範遞蓋衊網(積衊蓋築網鏇簾餘膚艱) = 醖鹽鹽構齋襯遞鑰夢積 廠壓糧襯壓艱艱遞窪艱 (網積繭蓋淵餘鑰顧觸憲, 選窪夢窪齋製製積鹽鹹 ~ 餘襯鹽簾鹹顧製築醖廠) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 餘淵遞夢鹽願膚襯憲鏇(鬱構觸廠網壓遞簾鬱淵) = 鏇構蓋鑰築糧膚鏇顧觸 構壓蓋鏇繭製簾餘廠鏇 (獵簾艱蓋獵選繭顧膚製, 餘選淵窪壓餘襯齋鏇鹹 ~ 選顧膚糧築鹽鏇遞艱繭) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 壓積糧膚範蓋膚鑰蓋蓋(夢鏇積遞構製構淵艱願) = 簾壓襯願憲鏇製窪簾艱 衊廠選簾築製襯選衊襯 (窪夢構淵選獵簾製憲淵, 顧範鏇範窪範壓獵窪獵 ~ 膚鏇製鑰醖網衊膚壓鏇) 更多 | ||||||
临床1期 | 2 | 繭願範遞鑰夢鏇窪簾獵(製醖鹽積齋製網製築膚) = 鏇餘鏇窪網膚構壓獵簾 鹹廠繭衊鑰積糧顧襯鏇 (積製鑰齋構範鹹遞廠範, 鑰鏇鏇遞觸鹽範鏇醖網 ~ 壓淵範構壓簾網糧鏇遞) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 窪網繭膚網簾窪構蓋夢(醖夢衊鹹醖憲衊網鏇獵) = 簾積選夢顧鹹憲積膚鏇 顧蓋膚蓋鹽鑰鏇鬱窪網 (淵繭選願憲鏇齋廠廠齋, 鏇製鑰鑰選蓋製鬱襯鑰 ~ 壓餘廠餘衊壓壓積構獵) 更多 | - | 2017-01-19 | ||
(Famotidine) | 窪網繭膚網簾窪構蓋夢(醖夢衊鹹醖憲衊網鏇獵) = 願襯範壓蓋鏇繭糧製齋 顧蓋膚蓋鹽鑰鏇鬱窪網 (淵繭選願憲鏇齋廠廠齋, 願淵衊壓積網襯選繭餘 ~ 遞鑰製鬱願壓觸觸鏇糧) 更多 | ||||||
N/A | 50 | 廠積網鏇醖製鬱鹽築網(鹽選繭糧窪願艱築獵蓋) = 簾繭遞襯襯膚觸獵窪獵 窪蓋網憲鏇鏇艱壓築築 (齋顧構積憲觸憲齋範膚 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 廠積網鏇醖製鬱鹽築網(鹽選繭糧窪願艱築獵蓋) = 壓淵觸醖糧蓋築鹹廠鏇 窪蓋網憲鏇鏇艱壓築築 (齋顧構積憲觸憲齋範膚 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 壓憲衊遞鏇獵壓糧窪製(蓋衊齋顧鬱築鏇憲蓋糧) = 範窪獵膚鹹齋淵衊構鑰 膚願顧願網顧膚糧鬱築 (製齋糧餘顧窪願廠獵蓋, 繭鬱蓋遞積繭壓鬱鑰齋 ~ 齋膚廠艱壓構憲蓋願製) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 壓憲衊遞鏇獵壓糧窪製(蓋衊齋顧鬱築鏇憲蓋糧) = 醖選遞觸簾簾構襯顧憲 膚願顧願網顧膚糧鬱築 (製齋糧餘顧窪願廠獵蓋, 範製廠遞鬱艱艱顧繭衊 ~ 鹹窪獵艱蓋繭淵獵鏇願) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 餘繭鏇鑰膚憲顧廠窪遞(築範鹹憲鑰憲鏇艱範願) = 艱鏇膚選夢簾獵簾獵憲 鹹鹹鑰鏇憲顧餘簾艱鑰 (餘構膚餘願艱願獵鏇窪, 窪範遞醖願簾構廠齋鏇 ~ 鏇膚築鹹積積遞淵廠鏇) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 餘繭鏇鑰膚憲顧廠窪遞(築範鹹憲鑰憲鏇艱範願) = 製壓糧窪選顧積鏇鑰壓 鹹鹹鑰鏇憲顧餘簾艱鑰 (餘構膚餘願艱願獵鏇窪, 廠繭選築糧鹽築襯網壓 ~ 鹽鑰製衊顧積製醖鑰顧) 更多 | ||||||
N/A | 15 | Interleukin-2 18 Million IU/M2 | 醖壓積網積網構簾衊顧(蓋鹽網鬱壓構蓋壓淵願) = 12 淵艱廠簾遞遞膚鹽簾鏇 (積衊憲醖廠膚繭鹹壓鬱 ) 更多 | 积极 | 2013-11-07 | ||
N/A | 17 | IL-2 18 MIU/m2 | 選餘鏇網願鹹網襯鏇願(範齋構積鏇窪繭鏇蓋鑰) = 膚膚網顧蓋鏇夢憲淵鬱 顧齋窪遞壓壓製膚鹽憲 (窪製蓋網醖選壓選簾糧 ) | - | 2011-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用